GENTAUR Belgium BVBA BE0473327336 Voortstraat 49, 1910 Kampenhout BELGIUM Tel 0032 16 58 90 45
GENTAUR U.S.A Genprice Inc,Logistics 547 Yurok Circle, SanJose, CA 95123
Tel (408) 780-0908, Fax (408) 780-0908, [email protected]

Did you know ? If you order before Friday 14h we deliver 90PCT of the the time next Tuesday, Gentaur another in time delivery

Pubmed ID: 30170128
Publication Date: 2018/08/29

Advances and highlights in primary immunodeficiencies in 2017.

This manuscript reviews selected topics in primary immunodeficiency diseases (PIDDs) published in 2017. These include (1) the role of follicular T cells in the differentiation of B cells and development of optimal antibody responses; (2) impaired nuclear factor κB subunit 1 signaling in the pathogenesis of common variable immunodeficiency, revealing an association between impaired B-cell maturation and development of inflammatory conditions; (3) autoimmune and inflammatory manifestations in patients with PIDDs in T- and B-cell deficiencies, as well as in neutrophil disorders; (4) newly described gene defects causing PIDDs, including exostosin-like 3 (EXTL3), TNF-α-induced protein 3 (TNFAIP3 [A20]), actin-related protein 2/3 complex-subunit 1B (ARPC1B), v-Rel avian reticuloendotheliosis viral oncogene homolog A (RELA), hypoxia upregulated 1 (HYOU1), BTB domain and CNC homolog 2 (BACH2), CD70, and CD55; (5) use of rapamycin and the phosphoinositide 3-kinase inhibitor leniolisib to reduce autoimmunity and regulate B-cell function in the activated phosphoinositide 3-kinase δ syndrome; (6) improved outcomes in hematopoietic stem cell transplantation for severe combined immunodeficiency (SCID) in the last decade, with an overall 2-year survival of 90% in part caused by early diagnosis through implementation of universal newborn screening; (7) demonstration of the efficacy of lentiviral vector-mediated gene therapy for patients with adenosine deaminase-deficient SCID; (8) the promise of gene editing for PIDDs using CRISPR/Cas9 and zinc finger nuclease technology for SCID and chronic granulomatous disease; and (9) the efficacy of thymus transplantation in Europe, although associated with an unexpected high incidence of autoimmunity. The remarkable progress in the understanding and management of PIDDs reflects the current interest in this area and continues to improve the care of immunodeficient patients.
Authors: Chinen Javier , Cowan Morton J ,


  1. [Last access 2018/08/29].

Related products :

Catalog number Product name Quantity
813095 DATE LBLS B-500 2017 25 DIA _ DATE LBLS B-500 2017 25 DIA AB Labels;Pack-CD; Width Dia 25 Height 10 lbls Pcs Per Pack
813094 DATE LBLS B-500 2017 15 DIA _ DATE LBLS B-500 2017 15 DIA AB Labels;Pack-CD; Width dia 15 Height 24 lbls Pcs Per Pack
813096 DATE LBLS B-500 2017 35 DIA _ DATE LBLS B-500 2017 35 DIA AB Labels;Pack-CD; Width Dia 35 Height 5 lbls Pcs Per Pack
813112 DATE LBLS 2017 DIA20 B-429 _ DATE LBLS 2017 DIA20 B-429 AB Labels;Pack-SH; Width Dia 20 Height 28 lbls Pcs Per Pack
813111 DATE LBLS 2017 DIA15 B-429 _ DATE LBLS 2017 DIA15 B-429 AB Labels;Pack-SH; Width Dia 15 Height 40 lbls Pcs Per Pack